ESSA Pharma (EPIX)
(Delayed Data from NSDQ)
$5.21 USD
-0.18 (-3.34%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $5.26 +0.05 (0.96%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMESSA Pharma (EPIX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$20.00 | $29.00 | $15.00 | 271.06% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for ESSA Pharma comes to $20.00. The forecasts range from a low of $15.00 to a high of $29.00. The average price target represents an increase of 271.06% from the last closing price of $5.39.
Analyst Price Targets (5 )
Broker Rating
ESSA Pharma currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, four are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/EPIX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/6/2024 | Piper Sandler | Joseph M Catanzaro | Strong Buy | Strong Buy |
5/16/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
12/14/2023 | Not Identified | Not Identified | Strong Buy | Strong Buy |
10/23/2023 | Bloom Burton & Company | David Martin | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 4 |
Average Target Price | $20.00 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 96 of 253 |
Current Quarter EPS Est: | -0.21 |